Pfenex Pitches Teriparatide Pen Against Lilly's Forteo as Partner Alvogen Files In Europe

 
• By Aidan Fry

Alvogen is conducting a study directing comparing its teriparatide delivery device with that of Lilly’s Forteo in a bid to be substitutable in the US for Pfizer’s original. The firm’s partner, Alvogen, has just filed the osteoporosis drug under Europe’s centralized procedure.  

Insulin pen
Pfenex is putting its teriparatide pen up against Lilly's Forteo device in a head-to-head study • Source: Shutterstock

More from Value Added Medicines

More from Products